Male Breast Self Exam

Total Page：16

File Type：pdf, Size：1020Kb

MALE BREAST SELF-EXAM Did you know that breast cancer can occur in men? Although it is not nearly as common as in women, it’s just as serious. In fact, men with breast cancer live two years less than women affected by the disease because most men don’t realize that they can get breast cancer, too. Approximately 2,550 new cases of invasive breast cancer are expected to be diagnosed SELF-EXAM INSTRUCTIONS in men each year. A man’s lifetime risk of breast cancer is approximately 1 in 1,000. STEP 1 Stand in front of a mirror with your arms on your hips to tighten your chest muscles and inspect yourself. Look for any changes such as a lump, misshapen breasts or nipple abnormalities. RISK FACTORS STEP 2 The following factors are associated with an increased risk of Raise your arms above your head male breast cancer: and continue to examine your breast • Men who carry a BRCA1 or BRCA2 gene mutation and armpit areas. • Men with a history of lymphoma and chest wall radiation • Family members who have had breast cancer or another STEP 3 Using mild pressure, move your form of cancer fingertips around the breast in a • Men who have received estrogen treatment or radiation circular motion starting with the nipple and extending outward. In exposure addition, feel for enlarged lymph Signs of breast cancer in men include breast lumps, inverted nodes in the armpit. nipples, changes in the skin around the nipple and enlarged lymph nodes in the armpit. STEP 4 In addition to performing a monthly self-exam, men at risk Extend your exam up to the for breast cancer also can receive mammogram screenings in collarbone and down to the lowest rib. Complete on both breasts. selected cases. For more information, talk with your doctor. Cancer Genetics and High Risk Care Center • 22 W. Underwood St., 2nd Floor Orlando, FL 32806 • (321) 841-GENE (4363) OrlandoHealthCancer.com.

Copy Link

Recommended publications

A Case of Male Breast Cancer with a BRCA Gene Mutation
CASE REPORT The Ochsner Journal 15:448–451, 2015 Ó Academic Division of Ochsner Clinic Foundation A Case of Male Breast Cancer with a BRCA Gene Mutation Martin A. Benjamin, MD,1 Adam I. Riker, MD, FACS2 1Department of Surgery, University of Illinois at Chicago, Chicago, IL 2Advocate Cancer Institute, Advocate Christ Medical Center, Oak Lawn, IL Background: Male breast cancer (MBC) is an uncommon malignancy with an incidence that accounts for about 1% of all breast cancer cases. It commonly presents as a locally advanced tumor that has already spread to the regional nodal basin. Similar to female breast cancers, MBC gene expression profiling and tumor studies help to detect molecular subtypes of tumors that correlate with clinical outcome and mortality rates. Case Report: We report a relatively uncommon case of a 64-year-old male with a BRCA1þ gene mutation that is also found to be HER2þ on receptor analysis. Initial diagnostic studies with mammography and ultrasound revealed a left-sided hypoechoic mass measuring 2.3 cm, located at the 11 o’clock position adjacent to the nipple-areolar complex. Whole body positron emission tomography–computed tomography scan revealed a hypermetabolic retroareolar left breast mass and enlarged, hypermetabolic left axillary lymph nodes. Final pathology revealed an infiltrating ductal carcinoma with a Nottingham histologic score of 3 (mitotic count score, 3; nuclear pleomorphism score, 3). Of the 19 lymph nodes examined, 15 had evidence of macrometastatic disease. Conclusion: This report highlights a novel case of MBC with a rare genotypic presentation. A need exists to further explore this disease process because the literature is scant with information regarding the long-term treatment and outcomes of MBC, especially in the genotypic form presented here.
[Show full text]
Male Breast Cancer - Wikipedia, the Free Encyclopedia Pagina 1 Van 5
Male breast cancer - Wikipedia, the free encyclopedia pagina 1 van 5 Male breast cancer From Wikipedia, the free encyclopedia Male breast cancer is a relatively rare cancer in Male breast cancer men that originates from Classification and external resources the breast. As it presents a ICD-10 C50 similar pathology as female breast cancer, assessment (http://apps.who.int/classifications/icd10/browse/2010/en#/C50) and treatment relies on ICD-9 175 (http://www.icd9data.com/getICD9Code.ashx? experiences and guidelines icd9=175),175.0 that have been developed (http://www.icd9data.com/getICD9Code.ashx? [1][2][3] in female patients. icd9=175.0),175.9 The optimal treatment is (http://www.icd9data.com/getICD9Code.ashx?icd9=175.9), currently not known. [4] OMIM 114480 (http://omim.org/entry/114480) MedlinePlus 000913 Contents (http://www.nlm.nih.gov/medlineplus/ency/article/000913.htm) eMedicine radio/115 (http://www.emedicine.com/radio/topic115.htm#) ■ 1 Incidence MeSH D001943 (http://www.nlm.nih.gov/cgi/mesh/2013/MB_cgi? ■ 2 Pathology field=uid&term=D001943) ■ 3 Diagnosis ■ 3.1 Staging ■ 4 Differences from female breast cancer ■ 5 Treatment ■ 5.1 Chemotherapeutic and hormonal options in male breast cancer ■ 6 Prognosis ■ 7 References Incidence About one percent of breast cancer develops in males. [4] It is estimated that about 2,140 new cases are diagnosed annually in the US and about 300 in the UK, and the number of annual deaths is about 450 in the US. [2][3] In a study from India, eight out of 1,200 (0.7%) male cancer diagnoses in a pathology review represented breast cancer.
[Show full text]
Evaluation of the Symptomatic Male Breast
Revised 2018 American College of Radiology ACR Appropriateness Criteria® Evaluation of the Symptomatic Male Breast Variant 1: Male patient of any age with symptoms of gynecomastia and physical examination consistent with gynecomastia or pseudogynecomastia. Initial imaging. Procedure Appropriateness Category Relative Radiation Level Mammography diagnostic Usually Not Appropriate ☢☢ Digital breast tomosynthesis diagnostic Usually Not Appropriate ☢☢ US breast Usually Not Appropriate O MRI breast without and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O Variant 2: Male younger than 25 years of age with indeterminate palpable breast mass. Initial imaging. Procedure Appropriateness Category Relative Radiation Level US breast Usually Appropriate O Mammography diagnostic May Be Appropriate ☢☢ Digital breast tomosynthesis diagnostic May Be Appropriate ☢☢ MRI breast without and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O Variant 3: Male 25 years of age or older with indeterminate palpable breast mass. Initial imaging. Procedure Appropriateness Category Relative Radiation Level Mammography diagnostic Usually Appropriate ☢☢ Digital breast tomosynthesis diagnostic Usually Appropriate ☢☢ US breast May Be Appropriate O MRI breast without and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O Variant 4: Male 25 years of age or older with indeterminate palpable breast mass. Mammography or digital breast tomosynthesis indeterminate or suspicious. Procedure Appropriateness Category Relative Radiation Level US breast Usually Appropriate O MRI breast without and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O ACR Appropriateness Criteria® 1 Evaluation of the Symptomatic Male Breast Variant 5: Male of any age with physical examination suspicious for breast cancer (suspicious palpable breast mass, axillary adenopathy, nipple discharge, or nipple retraction).
[Show full text]
Original Article Molecular Subtypes of Male Breast Cancer by Immunohistochemistry
Int J Clin Exp Med 2017;10(1):1670-1677 www.ijcem.com /ISSN:1940-5901/IJCEM0041401 Original Article Molecular subtypes of male breast cancer by immunohistochemistry Huiling Li1*, Yumei Yang2*, Dapeng Wang3, Zhengtian Li4, Dan Zhang5, Fengjuan Xu1 Departments of 1Medical Records and Statistics Room, 4General Surgery, 5Ultrasound, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Road, Harbin, China; 2Department of Operation Room, The Second Af- filiated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, China; 3Department of Human Resources, The Third Affiliated Hospital of Harbin Medical University, 150 Haping Road, Harbin, China. *Co-first authors. Received August 11, 2016; Accepted November 20, 2016; Epub January 15, 2017; Published January 30, 2017 Abstract: Male breast cancer is a rare disease, accounting for less than 1% of all breast cancer cases worldwide. Compared to female breast cancer, the incidence of male breast cancer has risen in recent years, and the relation- ship between molecular subtype and clinical behavior has rarely been studied. In this study, we examined the mo- lecular subtypes of male breast cancers based on the expression profile of immunomarkers and their association with clinicopathological features. A total of 98 male breast carcinoma patients were investigated retrospectively using immunostaining for estrogen receptor (ER), progesterone receptor (PR), HER2, Ki-67, and P53. Results were interpreted based on the molecular subtype classification of the 13th St Gallen International Expert Consensus (2013). HER2 expression that was 2+ or 3+ was also evaluated by fluorescent in situ hybridization (FISH) for further validation. The luminal subtype A was the most common in all patients (83.7%, 82/98), followed by the luminal subtype B (16.3%, 16/98).
[Show full text]
42 Male Breast Cancer C
42 Male Breast Cancer C. Bernard-Marty, E. Azambuja, L. Dal Lago, M.J. Piccart, and F. Cardoso 42.1 Introduction The earliest reference to breast cancer (BC) in men dates from 3000–2500 BCE, on an Egyptian papyrus [11], and the first clinical report was described in the 14th cen- tury by John of Arderne [71]. Carcinoma of the male breast is a relatively rare disease that accounts for less than 1% of all cases of cancer in men. Therefore, BC in men has largely taken a back seat to the worldwide effort to control this disease in women. Similarly, the literature regarding male BC consists mainly of case-control and retrospective studies involv- ing small numbers of patients [28]. The statistical accuracy of the clinical character- istics of male BC is not fully established and knowledge relevant to specific aspects of the disease in men is still limited. Consequently, treatment strategies have been largely guided by extrapolation from experience in women. In this chapter, the available information on risk, prognostic factors, clinical fea- tures, and treatment modalities of male BC has been summarized. Tailored pro- spective clinical trials in this disease, through large Intergroup networks, should be initiated. 42.2 Incidence According to the American Cancer Society, of the 212,600 new cases of BC diag- nosed in 2003, 1,300 (1%) were diagnosed in men and resulted in 400 deaths (30%) [39]. In contrast to the increasing incidence of BC in women, the incidence of BC in men has remained stable over the past 4 decades [47].
[Show full text]
Breast Cancer in Men: a 10-Year Experience © Permanyer 2019 © Permanyer 2019 of an Oncology Reference Center in Northeast
www.journalofcancerology.com PERMANYER J Cancerol. 2019;6:21-7 www.permanyer.com JOURNAL OF CANCEROLOGY HOT TOPIC Breast cancer in men: A 10-year experience © Permanyer 2019 © Permanyer 2019 of an oncology reference center in Northeast . Mexico CARLOS EDUARDO SALAZAR-MEJÍA*, ALAN BURGUETE-TORRES, JUAN FRANCISCO GONZÁLEZ-GUERRERO, DANIEL ALbeRTO GALLEGOS-ARGUIJO, BLANCA OTILIA WImeR-CASTILLO, BRENDA ALEJANDRA SAMANIEGO-SÁENZ, LOURDES PAOLA CHAPA-MONTALVO AND OSCAR VIDAL-GUTIÉRREZ of the publisher Centro Universitario Contra el Cáncer, University Hospital “Dr. José Eleuterio González” and Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, México ABSTRACT Introduction: Breast cancer in men (BCM) accounts for approximately 1% of all breast cancer cases. The present study aimed at describing the clinical and demographic characteristics of BCM in Mexican population. Methods: We performed a retrospective analysis of the men with newly diagnosed breast cancer treated in an oncology referral center in Northeast Mexico from 2007 to 2017. Results: Fifteen patients were included in the analysis. Mean age at diagnosis was 60.7 years and median time from diagnosis to the start of treatment was 2 months. About 73% of patients presented with locoregional disease (clinical stage [CS] I-III) and 26.7% were classified as Stage IV disease on their first assessment. All patients had invasive ductal carcinoma and 60.0% were Grade II tumors. Twelve cases were positive for hormone receptors and none showed overexpression of human epidermal growth factor receptor 2. Regarding primary treatment, 12 patients underwent a modified radical mastectomy and two underwent breast-conserving surgery. The majority of patients received chemotherapy and radiotherapy in the adjuvant setting and tamoxifen was the drug of choice in all patients considered as candidates for hor- monal therapy.
[Show full text]
Of Male Breast Cancer
2.6 HOURS Continuing Education ORIGINAL RESEARCH By Eileen Thomas, PhD, RN Men’s Awareness and Knowledge of Male Breast Cancer A STUDY OF MEN A T HIGHER RISK PROVIDES A N EVIDENCE -B A SED UNDER - ST A NDING OF MEN ’S PERCEPTIONS OF THIS DISE A SE . reast cancer in men is uncommon, account - ABSTRACT ing for less than 1% of all breast cancers This article reports on the findings of a qualitative Objective: and less than 1% of all carcinomas in men.1 study that explored the awareness and knowledge of male breast Incidence trends are less clear. One large U.S. cancer among English-speaking men. The primary goal was to elicit population–based study by Giordano and information to guide both clinical practice and the development of Bcolleagues revealed that, between 1973 and 1998, the gender-specific educational interventions. incidence of male breast cancer increased by 26%, Methods: Interviews with 28 adult men, all of whom had no while that of female breast cancer rose by 52%.1 More history of breast cancer themselves but had at least one maternal recently, the American Cancer Society (ACS) has re - blood relative with the disease, were conducted and analyzed, using ported that although the rate of female breast cancer qualitative methods, to describe participants’ awareness of male has been declining,2 “the number of breast cancer cases breast cancer, their knowledge of the disease, and how they thought in men relative to the population has been fairly stable awareness of male breast cancer could be increased in health care over the last 30 years.”3 The ACS also estimates that, providers and the lay public.
[Show full text]
Fibroadenoma in the Male Breast: Truth Or Myth?
Ulus Cerrahi Derg 2016; 32: 208-211 Case Series DOI: 10.5152/UCD.2015.3120 Fibroadenoma in the male breast: Truth or Myth? Puneet Agarwal, Gaurav Kohli ABSTRACT Truth or myth is seldom encountered in the practice of surgery, especially in cases of breast diseases. Yet, even after thousands of years of treating breast disease by surgeons/healers, fibroadenoma in the male breast seems to be a myth, due to the absence of fibro-glandular tissue. We wish to break this myth by our own experience as well as other studies by others all over the world, and unveil the truth that fibroadenoma in the male breast is a definitive entity and has a prevalence among the vast spectrum of breast diseases. Keywords: Male, breast, fibroadenoma, tumour, benign lesion INTRODUCTION Diseases of the breast have influenced the world since ancient times. Fibroadenoma has almost always been associated with premenopausal female breast. A clinical diagnosis of fibroadenoma in the male breast is unexpected due to the lack of fibro-glandular tissue in normal males. Only a few cases of fibro- adenomas in males have been reported in the literature; most of the reported cases involving male-to- female transsexuals (1, 2), or iatrogenic male fibroadenomas due to estrogen therapy for a medical con- dition in the elderly such as prostate carcinoma (3). Benign conditions such as gynecomastia, lipoma, epidermal inclusion cysts, and intraductal papilloma may mimic male breast cancer (4, 5). This article will attempt to highlight the truth behind the entity of fibroadenoma in males. CASE SERIES Over the last few years, we have come across 3 male cases with a breast lump.
[Show full text]
The Endocrinology of Male Breast Cancer
25 6 Endocrine-Related I S Fentiman Male breast cancer 25:6 R365–R373 Cancer endocrinology REVIEW The endocrinology of male breast cancer Ian S Fentiman Research Oncology, Guy’s Hospital, London, UK Correspondence should be addressed to I S Fentiman: [email protected] Abstract Male breast cancer (MBC) is a rare disease but, as a result of epidemiological Key Words collaborations, there is now greater clarity concerning endocrine risk factors. The f male breast cancer significant rise in global age-standardised mean BMI in men is likely to lead to increases f risk factors in incidence of maturity-onset diabetes and MBC. The metabolic changes accompanying f obesity obesity decrease androgens and sex hormone-binding globulin (SHBG), thereby f Klinefelter’s increasing available oestrogens. The higher rates of MBC in North and Equatorial Africa f endocrine therapy are largely due to liver damage from endemic bilharziasis and hepatitis B causing elevated oestradiol (E2) levels from hepatic conversion of androgen. Klinefelter’s syndrome (XXY) is associated with a 50-fold increase in incidence of MBC compared with XY males, and this is the most pronounced evidence for testicular malfunction amplifying risk. Delay in presentation means that up to 40% of cases have stage III or stage IV disease at diagnosis. No randomised controlled trials have been reported on endocrine treatment of advanced disease or adjuvant/neoadjuvant therapy following or preceding surgery. Tamoxifen is the most effective endocrine therapy, but side effects can lead to non-compliance in a substantial number of men. Aromatase inhibitors are less effective because they do not inhibit testicular oestrogen production.
[Show full text]
Male Breast Cancer: Management and Followup Recommendations
ORIGINAL ARTICLE Male Breast Cancer: Management and Follow-up Recommendations John V. Kiluk, MD,* Marie Catherine Lee, MD,* Catherine K. Park, MD, MPH,* Tammi Meade, BS, BA,* Susan Minton, DO,* Eleanor Harris, MD,* Jongphil Kim, PhD, and Christine Laronga, MD* *Comprehensive Breast Program, Department of Women’s Oncology and Department of Biostatistics, H. Lee Mofﬁtt Cancer Center, Tampa, Florida 33612 n Abstract: National Comprehensive Cancer Network (NCCN) guidelines for female breast cancer treatment and surveillance are well established, but similar guidelines on male breast cancers are less recognized. As an NCCN institu- tion, our objective was to examine practice patterns and follow-up for male breast cancer compared to established guide- lines for female patients. After Institutional Review Board approval, a prospective breast database from 1990 to 2009 was queried for male patients. Medical records were examined for clinico-pathological factors and follow-up. The 5-year survival rates with 95% conﬁdence intervals were estimated using Kaplan–Meier method and Greenwood formula. Of the 19,084 patients in the database, 73 (0.4%) were male patients; 62 had complete data. One patient had bilateral synchronous breast cancer. The median age was 68.8 years (range 29–85 years). The mean ⁄ median invasive tumor size was 2.2 ⁄ 1.6 cm (range 0.0–10.0 cm). All cases had mastectomy (29 with axillary node dissection, 23 with sentinel lymph node biopsy only, 11 with sentinel node biopsy followed by completion axillary dissection). Lymph node involvement occurred in 25 ⁄ 63 (39.7%). Based on NCCN guidelines, chemotherapy, hormonal therapy, and radiation are indicated in 34 cases, 62 cases, and 14 cases, respectively.
[Show full text]
FDA: Male Breast Cancer: Developing Drugs for Treatment
Male Breast Cancer: Developing Drugs for Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence (OCE) Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) August 2020 Clinical/Medical Male Breast Cancer: Developing Drugs for Treatment Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353; Email: [email protected] https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs and/or Office of Communication, Outreach, and Development Center for Biologics Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 71, Room 3128 Silver Spring, MD 20993-0002 Phone: 800-835-4709 or 240-402-8010; Email: [email protected] https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics- guidances U.S. Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence (OCE) Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) August 2020 Clinical/Medical Contains Nonbinding Recommendations TABLE OF CONTENTS I. INTRODUCTION............................................................................................................
[Show full text]
Male Breast Carcinoma- with Numerous Histological Patterns - an Interesting Case Report
IP Archives of Cytology and Histopathology Research 2020;5(2):173–176 Content available at: iponlinejournal.com IP Archives of Cytology and Histopathology Research Journal homepage: www.innovativepublication.com Case Report Male breast carcinoma- with numerous histological patterns - an interesting case report Sankappa P. Sinhasan1,*, Subashini R1, Ramachandra V Bhat1 1Dept. of Pathology, Indira Gandhi Medical College & Research Institute, Puducherry, India ARTICLEINFO ABSTRACT Article history: Male Breast Carcinoma (MBC) is a rare condition accounting for <1% of all breast carcinomas. The Received 15-04-2020 risk factor includes hormonal imbalance, Klinefelter syndrome, testicular disorders, radiation exposure, Accepted 12-05-2020 alcoholism and antiandrogenic medication. MBC clinically manifests as painless palpable mass sometimes Available online 11-06-2020 masquerading gynecomastia. Compared with female breast cancer, male breast carcinoma presents slightly older age at diagnosis with large tumor size and most of the tumors hormone receptor positive. We come across chronic alcoholic male presented with fungating growth over left breast. Cytology revealed Keywords: neuroendocrine type of inﬁltrating ductal carcinoma cells, whereas biopsy showed various histological Male Breast Carcinoma patterns in sections from different areas making this case interesting one. Immunohistochemically, it was Comedocarcinoma positive for estrogen and progesterone receptor but negative for Her2neu marker. Neuroendocrine Cribriform © 2020 Published by Innovative Publication. This is an open access article under the CC BY-NC license Schirrous (https://creativecommons.org/licenses/by-nc/4.0/) Mucinous 1. Introduction biopsy revealed six different histological patterns making this case interesting one. Male breast cancer (MBC) is very rare and constitutes 0.5-1% of all patients with breast cancer.
[Show full text]